Evidence map›Paper›PMID 42383348›Full record

ArticleNano letters2026

Development of a Nanoscale Protein-Protein Mapping of PDE4 Interface-Disrupting Peptides.

Sibo Lyu, Aleksandra Judina, Jiayue Ling, Thomas A Wright, Aditi Kulkarni, Jiarong Fu, Iyobel Kibreab, George Baillie, Prashant Kumar Srivastava, Julia Gorelik

Abstract read
In one paragraph

Article in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sibo LyuCardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, LondonW12 0NN, U.K.ORCID 0009-0002-0539-4195
Aleksandra JudinaCardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, LondonW12 0NN, U.K.
Jiayue LingSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Avenue, GlasgowG12 8QQU.K.
Thomas A WrightSchool of Cancer Sciences, University of Glasgow, University Avenue, GlasgowG12 8QQ, U.K.
Aditi KulkarniCardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, LondonW12 0NN, U.K.
Jiarong FuCardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, LondonW12 0NN, U.K.ORCID 0000-0003-4130-6746
Iyobel KibreabCardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, LondonW12 0NN, U.K.
George BaillieSchool of Cardiovascular and Metabolic Health, University of Glasgow, University Avenue, GlasgowG12 8QQU.K.
Prashant Kumar SrivastavaCardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, LondonW12 0NN, U.K.
Julia GorelikCardiac Section, National Heart and Lung Institute (NHLI), Faculty of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, LondonW12 0NN, U.K.

Funding

British Heart Foundation RG/F/22/110081
6 · The paper itself

Abstract

Spatially confined β-adrenergic receptor-cAMP nanodomain signaling depends on scaffolded protein-protein interactions (PPIs), yet converting such nanointerfaces into cell-active disruptor peptides remains challenging. Here, we identify a previously unrecognized phosphodiesterase 4A (PDE4A)-filamin A complex in human cardiac tissue that is disrupted in dilated cardiomyopathy. To target this interaction, we developed a nanodomain-resolved AlphaFold3 workflow integrating interface-recurrence filtering, orthogonal docking, and peptide-binding site inference to define a tractable binding region. This approach identified a filamin A docking sequence spanning R2520-H2528, which was optimized to RLVSNHSLH and rendered cell-permeant by N-terminal polyarginine tagging. In ventricular cardiomyocytes, the peptide reduced PDE4A-filamin A proximity and selectively attenuated β-adrenergic cAMP signaling in cytosolic and sarcolemmal compartments, measured by FRET biosensors. This work establishes a potential transferable strategy for translating predicted scaffolded PPI nanointerfaces into functional disruptor peptides and highlights compartmentalized signaling complexes as actionable targets for selective cellular modulation.

Indexed as

Cardiomyopathy, DilatedCyclic Nucleotide Phosphodiesterases, Type 4FilaminsPeptidesProtein Interaction MappingAnimalsBinding SitesCyclic AMPHumansMyocytes, CardiacProtein BindingSignal TransductionCyclic AMPCyclic Nucleotide Phosphodiesterases, Type 4FilaminsPeptidescomputational frameworkDisruptor peptidePDEprotein−protein interaction

Identifiers

PMID42383348
PMCPMC13475046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.